All News

The company pointed the President to existing published research and pledged to post more to its site.

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using War-Lock technology, enhancing treatment options.

Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing treatment options and patient outcomes.

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their unique OdyssION drug discovery platform.

The feature will be available on the company’s platform Nuro.

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and safety in care.

Wayrilz is the first Bruton’s tyrosine kinase inhibitor to be approved for adults with persistent or chronic immune thrombocytopenia who have not responded adequately to prior therapy.

Johnson and Johnson halts Nipocalimab's development for rheumatoid arthritis after Phase 2a trial shows no significant benefits over existing therapies.

The blood purification technology is used for the treatment of severe treatment-refectory systematic lupus erythematosus (SLE).

Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.

Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.

A monthly roundup of business and people news in the pharmaceutical industry.

Replicate Bioscience partners with Novo Nordisk to advance self-replicating RNA therapies for obesity and type 2 diabetes, enhancing innovative treatment options.

Amylyx Pharmaceuticals halts Amx0035's Orion program for PSP, shifting focus to Avexitide and other promising treatments for neurodegenerative diseases.

Lawyers for Monarez argue that only the president can fire her and that she has no plans to resign.

Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients, pending FDA approval.

FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.

ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing maternal and fetal health.

Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and automation.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic improvements in the Phase III Attain-2 trial, paving the way for global regulatory submissions.

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new treatments.

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as the companies explore a novel drug candidate for severe neurological disorders.

The acquisition adds Furoscix, an FDA-approved furosemide infusion therapy for chronic heart failure and kidney disease, while strengthening MannKind’s pipeline and commercial presence in cardiometabolic and orphan lung diseases.

Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East Coast supporting next-generation obesity treatments and metabolic medicines as part of Roche’s broader $50 billion U.S. investment in innovation, job creation, and advanced biomanufacturing.

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel tasked with reviewing vaccine safety and effectiveness, despite controversy surrounding his past calls for vaccine withdrawal.

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare sectors are helping to create innovative solutions for global markets.

New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular events.

Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development for the treatment of major depressive disorder.

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of Imdelltra, securing an $885 million upfront payment and potential additional royalties, while retaining rights to other pipeline assets and future high-sales milestones.